Reuters logo
BRIEF-Ligand to acquire Crystal Bioscience
October 4, 2017 / 8:19 PM / 2 months ago

BRIEF-Ligand to acquire Crystal Bioscience

Oct 4 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments

* Ligand Pharmaceuticals Inc - ‍transaction expected to be accretive to revenue and earnings beginning in 2018​

* Ligand Pharmaceuticals Inc - Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones

* Ligand Pharmaceuticals Inc says ‍including acquisition, Ligand now expects 2017 total revenues to be at least $134 million​

* Ligand Pharmaceuticals Inc says estimates with revenue of $134 million, FY 2017 adjusted earnings per share would be approximately $2.93​

* Ligand Pharmaceuticals Inc expects 2017 earnings per share would be approximately $2.93 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below